-
This Israeli Cannabis Operator Anticipates $95.4M In Revenue Despite Gaza Conflict
Monday, April 1, 2024 - 2:13pm | 819InterCure Ltd. (NASDAQ:INCR) (TASE: INCR), an Israeli cannabis company doing business as Canndoc, announced its preliminary results on Monday for the full year of 2023. Preliminary H2 2023 Financial Highlights Revenue is estimated at NIS 140 million ($38.1 million). Adjusted EBITDA is estimated to...
-
Canndoc Reports Record Revenue Amid Cannabis Market Turmoil
Friday, September 1, 2023 - 9:48am | 621InterCure Ltd. (NASDAQ: INCR) (TASE: INCR), which is doing business as Canndoc, reported its financial and operating results on Thursday for the three and six months ended June 30, 2023, "The first half of 2023 is another solid performance for InterCure, with year-over-year revenue...
-
Organigram Q4 Revenue Grows 83% YoY, Provides Outlook
Tuesday, November 29, 2022 - 8:49am | 815Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI) released its results for the fourth quarter and year ended August 31, 2022, revealing net revenue in FY 2022 increased 84% to $145.8 million from $79.2 million in the previous year primarily due to an increase in recreational and international...
-
Israeli Cannabis Producer Touts Record Q3 Revenue, Gross Profit Increase
Tuesday, November 15, 2022 - 11:20am | 464InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR), which is doing business as Canndoc, announced on Tuesday its financial and operating results for the third quarter ended September 30, 2022. "We continued to execute on our international expansion plans building our footprint...
-
InterCure Reports Record Preliminary Q2 2022 Revenue – More Than Double YoY
Thursday, July 21, 2022 - 10:17am | 461InterCure Ltd. (NASDAQ: INCR) (TSX:INCR.U) (TASE:INCR) released preliminary financial results for the second quarter of 2022, revealing record revenue estimated to be CA$36 million ($27,86 million), more than double the revenues of the second quarter of 2021 and representing sequential growth of...
-
InterCure Reports Record FY 2021 Revenue Of $89M, Q4 Adjusted EBITDA Spikes 140% YoY
Monday, April 4, 2022 - 9:53am | 750InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR), which is doing business as Canndoc, has announced its estimated financial and operating results for the fourth quarter and year ended December 31, 2021. Q4 Key Financial & Operating Highlights Record revenue of CA$33 million ($26.4...
-
InterCure To Acquire Israel-Based Medical Cannabis Producer Better For $35M
Wednesday, February 16, 2022 - 9:38am | 496InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR), which is doing business as Canndoc, has signed a definitive agreement to acquire Cann Pharmaceutical Ltd., also known as Better. Under the terms of the agreement, InterCure will acquire 100% of Better’s shares, which includes “...
-
Canndoc To Purchase Better Holdings, 50% Of Cann Pharmaceutical For $35M
Monday, April 5, 2021 - 5:21pm | 333InterCure LTd. (TASE: INCR), doing business as Canndoc, is poised to acquire medical cannabis brand Better Holdings. The Israeli cannabis company inked a letter of intent to purchase 100% of Cann Pharmaceutical Ltd.'s shares, including Better’s Israel-based operations and 50% of Cann'...
-
Subversive Debuts In Israel Via Qualifying Transaction With InterCure
Tuesday, January 26, 2021 - 5:38pm | 276Subversive Real Estate Acquisition REIT LP (OTCQX: SBVRF) (NEO: SVX.U) is teaming up with Israeli cannabis company InterCure Ltd. “We are excited to announce today’s qualifying transaction, which, upon closing, will allow our shareholders to participate in the upside of the Israeli...
-
Teva Dips Into Medical Marijuana Market With Canndoc Distribution Deal
Friday, September 13, 2019 - 8:14am | 666Cannabis companies have been feverishly stitching up partnerships with each other, beverage companies and biopharma companies to tap into the market's huge potential. Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has taken a giant leap of faith in this direction. The Canna-Pharma...